Dr. Aleksandar Sekulic on Vismodegib for Basal-Cell Nevus Syndrome
1 Views
administrator
07/01/23
Aleksandar Sekulic, MD, PhD, Assistant Professor of Dermatology, Mayo Clinic, Scottsdale, AZ, discusses the use of the oral hedgehog pathway inhibitor vismodegib (Erivedge) for the treatment and prevention of basal-cell carcinoma (BCC) in patients with basal-cell nevus syndrome, a rare disorder also known as Gorlin syndrome.
For more resources on skin cancer and melanoma, visit http://www.onclive.com/specialty/melanoma
-
Category
Show more
Facebook Comments
No comments found